RCS - OptiBiotix Health - Marketing update

OptiBiotix HealthAnnouncement

25/02/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200225:nRSY9473Da

RNS Number : 9473D  OptiBiotix Health PLC  25 February 2020

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Marketing update

 

OptiBiotix Health plc (AIM:
OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, provides the following marketing update.

 

SlimBiome® is Generally Recognized as Safe ("GRAS")

OptiBiotix has self-affirmed its patented SlimBiome® ingredient is GRAS per
US Code 21 CFR 170.30. This affirmation is based on a complete evaluation of
all ingredients and processes used to manufacture SlimBiome® and confirmation
of GRAS status for all materials used in the SlimBiome® formulation. GRAS
status is a United States Food and Drug Administration (FDA) requirement for
any ingredient or additive used in food products sold in the United States.

 

Online Subscription Service

OptiBiotix has introduced a subscription service for its on line store
www.optibiotix.online (http://www.optibiotix.online) . The service allows
customers to subscribe to repeat orders and benefit from a discount on product
and delivery costs. Currently the first order is 10% off, with subsequent
orders thereafter at a 15% discount to help encourage continual subscription.
The subscription service has been introduced to improve customer convenience
and help OptiBiotix determine future demand allowing better inventory
management, and support ongoing supplier discussions to reduce the cost of
goods and improve margins.

 

Investor discount code INVESTOR20

OptiBiotix appreciates the ongoing support and feedback from its investors on
existing and new products. This helps the Company improve existing products
(e.g. a new smaller CholBiomeX3 tablet), and feeds directly into its new
product development pipeline. It plans to launch a range of new products with
retail partners, and on its online store in the coming months. These include a
range of healthy snacks (e.g fruit and fibre gummies) under the SnackSmart™
brand, pancake mixes, a new blueberry and raspberry snack bar, and an
extension of its breakfast range to include porridge containing SlimBiome®.

 

In recognition of the valuable feedback OptiBiotix receives from its
investors, and to broaden investor engagement in the development of new
products and the success of OptiBiotix, the Company has created a new discount
code, INVESTOR20. This gives investors 20% off the list price of the online
product when spending over £45. The code cannot be used with other discount
codes but can be used with the subscription service. This means that investors
who subscribe and use the INVESTOR20 code can get 30% off all products (10%
for subscribing and 20% off with the investor code). The code is valid for one
month which may be extended or new codes offered to support product launches.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix is pleased to update
investors on a number of developments which support the commercialisation of
its ingredients and products. Self affirming SlimBiome® as GRAS will support
commercialisation of SlimBiome® as a food ingredient in the $7.6bn (2020,
Statistica) food and beverage market in the USA. The subscription service and
investor discount code is designed to improve customer convenience, improve
inventory management, and support the development and launch  of a range of
new products on www.optibiotix.online (http://www.optibiotix.online) and with
retail partners in future months."

 

 

For further information, please contact:

 

 OptiBiotix Health plc                                         www.optibiotix.com (http://www.optibiotix.com)
 Stephen O'Hara, Chief Executive                               Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                          Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 finnCap (Broker)                                              Tel: 020 7220 0500
 Geoff Nash / Kate Bannatyne (Corporate Finance)
 Camille Gochez (Corporate Broking)

 goetzpartners securities Limited    Tel: 0203 859 7725
 Ulrich Kinzel

 Walbrook PR Ltd                                               Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than 20 international food
and healthcare supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of food
products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NRASELFILESSEEE